1. Home
  2. KG vs RPID Comparison

KG vs RPID Comparison

Compare KG & RPID Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

KG

Kestrel Group Ltd.

N/A

Current Price

$5.19

Market Cap

87.3M

Sector

Finance

ML Signal

N/A

Logo Rapid Micro Biosystems Inc.

RPID

Rapid Micro Biosystems Inc.

HOLD

Current Price

$1.13

Market Cap

84.8M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
KG
RPID
Founded
N/A
2006
Country
Bermuda
United States
Employees
N/A
N/A
Industry
Property-Casualty Insurers
Medical Specialities
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
87.3M
84.8M
IPO Year
2025
2021

Fundamental Metrics

Financial Performance
Metric
KG
RPID
Price
$5.19
$1.13
Analyst Decision
Strong Buy
Analyst Count
0
1
Target Price
N/A
★ $8.00
AVG Volume (30 Days)
37.7K
★ 307.6K
Earning Date
05-15-2026
05-08-2026
Dividend Yield
N/A
N/A
EPS Growth
★ 1819.15
2.78
EPS
N/A
★ N/A
Revenue
★ $34,049,000.00
$33,587,000.00
Revenue This Year
N/A
$19.12
Revenue Next Year
N/A
$18.42
P/E Ratio
★ N/A
N/A
Revenue Growth
★ 785.08
19.74
52 Week Low
$4.82
$1.08
52 Week High
$27.55
$4.94

Technical Indicators

Market Signals
Indicator
KG
RPID
Relative Strength Index (RSI) 36.33 25.73
Support Level N/A N/A
Resistance Level $12.02 $2.18
Average True Range (ATR) 0.49 0.07
MACD -0.03 0.01
Stochastic Oscillator 21.40 16.67

Price Performance

Historical Comparison
KG
RPID

About KG Kestrel Group Ltd.

Kestrel Group Ltd specializes in providing fronting services to insurance program managers, MGAs, reinsurers, and reinsurance brokers with two reportable segments: Program Services and Legacy Reinsurance. The Group facilitates insurance transactions utilizing its management contracts with four insurance carriers. Its line business includes casualty, workers' compensation, catastrophe-exposed property, and non-catastrophe-exposed property, with diverse risk durations, sizes, and product types.

About RPID Rapid Micro Biosystems Inc.

Rapid Micro Biosystems Inc is a life sciences technology company. Its technology uses a sensitive camera and the natural autofluorescence of living cells to identify and quantify microbial growth faster and more accurately than the traditional method, which relies on the human eye. The company develops, manufactures, markets, and sells Growth Direct systems (Systems), proprietary consumables, laboratory information management system (LIMS) connection, and other software and services to address rapid microbial analysis used for quality control in the manufacture of pharmaceuticals, medical devices, and personal care products. Geographically, it generates maximum revenue from the United States, and the rest from Switzerland, Germany, Japan, and all other countries.

Share on Social Networks: